Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
JERSEY CITY, N.J., June 13, 2017 -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer, will participate in a panel at the 2017 BIO International Conference at the San Diego Convention Center on Tuesday, June 20, 2017, at 4:15 p.m. PT. The panel, “Antifungus Among Us: Recognizing Vulnerability and Opportunity with the Next-Generation of Antifungals,” will focus on the growing global health epidemic and highlight the urgent needs and opportunities in the antifungal space.
About SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is the first representative of a novel intravenous and oral triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Cammy Duong MacDougall Biomedical Communications Tel: 781-591-3443 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
